ORIGINAL RESEARCH article
Front. Oncol.
Sec. Breast Cancer
Trastuzumab Deruxtecan in Advanced Breast Cancer: A Real-World Study of Efficacy and Safety in Chinese Cohort with HER2-Positive and HER2-Low Expression
Provisionally accepted
- department in oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: To explore the safety and real-world efficacy of trastuzumab deruxtecan in Chinese patients with advanced breast cancer that is either HER2-positive or HER2-low expression. Methods: A retrospective analysis was conducted on 104 patients diagnosed with advanced breast cancer who received trastuzumab deruxtecan treatment at the Affiliated Hospital of Xuzhou Medical University, with the study period spanning from January 2023 to September 2025. The primary endpoint of the study was progression-free survival, and the secondary endpoints were objective response rate, disease control rate, and safety. Progression-free survival was analyzed using the Kaplan-Meier method and log-rank test. Results: Among 104 patients, the median progression-free survival was 8.8 months in those with HER2-low expression, whereas HER2-positive patients exhibited a longer median progression-free survival of 14.2 months, along with superior objective response rate and disease control rate. Adverse events were reported in all patients, predominantly Grade I-II, with no new safety signals detected. Conclusions: Consistent with findings from previous clinical trials, real-world evidence from this study confirms that trastuzumab deruxtecan exhibits efficacy in patients with advanced breast cancer across all HER2 expression statuses and safety profile is manageable. Earlier initiation of trastuzumab deruxtecan may maximize survival benefits. These findings help bridge the gap between clinical trial evidence and routine clinical practice.
Keywords: Advanced breast cancer, HER2, Real-world study, T-DXd, trastuzumab deruxtecan
Received: 02 Dec 2025; Accepted: 10 Feb 2026.
Copyright: © 2026 Liang, Kong and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Feifei Kong
Zhengqiu Zhu
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.